Disposals

6 Months Ended

Jun. 30, 2026

Discontinued Operations and Disposal Groups [Abstract]

On May 1, 2025, the Company closed the disposition of an incontinence business that was included in its Wellness at Home segment. In connection with the closing, the Company received gross proceeds of $69.1 million.

On June 9, 2025, the Company closed the disposition of an infusion business that was included in its Wellness at Home segment. In connection with this transaction, the Company received gross proceeds of $53.5 million and was entitled to potential contingent payments of up to $12.5 million based upon the achievement of certain conditions in accordance with the terms of the sale agreement. In June 2026, the Company received $6.3 million related to the contingent payments, which is included in gain on sale of businesses recognized in the consolidated statements of operations for the three and six months ended June 30, 2026. The Company does not expect to receive the remaining contingent payments.

The dispositions described above did not represent a strategic shift for the Company. As such, they did not meet the requirements to be classified and presented as discontinued operations.

The following table presents the pre-tax gain recognized during the three and six months ended June 30, 2025 associated with the dispositions described above (in thousands):


Gross sales proceeds	$	122,336
Net assets sold	(90,111)
Total	$	32,225

The carrying value of the net assets sold at their respective closing dates associated with the dispositions described above were as follows (in thousands):


Cash	$	5,161
Accounts receivable	12,667
Inventory	1,770
Prepaid and other current assets	1,142
Equipment and other fixed assets, net	909
Operating lease right-of-use assets	776
Goodwill	80,943
Identifiable intangible assets, net	2,435
Other assets	11
Accounts payable and accrued expenses	(13,451)
Operating lease liabilities	(802)
Other liabilities	(1,450)
Total	$	90,111

Held for Sale and Discontinued Operations

In June 2026, the Company's board of directors approved the divestiture of the Company's Diabetes Health business. On July 19, 2026, the Company entered into a definitive agreement to sell the Diabetes Health business for $235.0 million in cash, subject to customary purchase price adjustments. The transaction is expected to close in the first quarter of 2027, subject to regulatory review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and other customary closing conditions. The Diabetes Health business provides medical devices, including continuous glucose monitors and insulin pumps, and related services to patients for the treatment of diabetes. As a result of this transaction, the Diabetes Health business met the criteria to be reported as discontinued operations. Therefore, the Company has reported the results of the Diabetes Health business, including the results of operations, and related assets and liabilities, as discontinued operations for all periods presented herein.

The following table summarizes the major classes of assets and liabilities classified as held for sale (in thousands):


	June 30, 2026		December 31, 2025
Assets
Inventory	$	34,219	$	36,354
Equipment and other fixed assets, net	6,413		6,763
Goodwill	83,801		83,801
Identifiable intangible assets, net	43,665		49,347
Total assets held for sale - discontinued operations	$	168,098	$	176,265
Liabilities
Contract liabilities	$	560	$	504
Total liabilities held for sale - discontinued operations	$	560	$	504

The following table summarizes the results of discontinued operations (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
Net revenue	$	154,440	$	143,272	$	294,365	$	276,607
Costs and expenses:
Cost of net revenue	132,619		124,402		256,675		242,877
General and administrative expenses	2,378		2,173		4,402		4,132
Depreciation and amortization, excluding patient equipment depreciation	2,893		3,139		5,828		6,281
Income from discontinued operations before income taxes	$	16,550	$	13,558	$	27,460	$	23,317
Income tax expense	5,163		3,111		7,096		6,447
Net income from discontinued operations, net of tax	$	11,387	$	10,447	$	20,364	$	16,870

The following table provides significant non-cash operating and investing cash flow information for the Company's discontinued operations:


	Six Months Ended June 30,
	2026		2025
Operating activities:
Depreciation and amortization, including patient equipment depreciation	$	11,083	$	10,839
Reduction in the carrying amount of operating lease right-of-use assets	267		450
Equity-based compensation	325		225
Investing activities:
Purchases of equipment and other fixed assets	$	5,016	$	4,152